OncoNano Medicine to Present Preclinical Data for ON-BOARDtm Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
OncoNano Medicine, Inc. today announced it will be presenting positive preclinical data detailing delivery of interleukin-12 (IL-12) with the ON-BOARDtm platform at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 1-5, 2023 in San Diego, California.
ON-BOARDtm is an ultra pH-sensitive tumor delivery platform designed to minimize systemic exposure and toxicity by protecting oncology intervention payloads and releasing them specifically in the acidic tumor microenvironment. The poster presentation will detail encapsulation and delivery of IL-12, a potent pleiotropic cytokine, using ON-BOARDtm in immunocompetent mice.
Presentation Overview
Title: Encapsulation of IL-12 with an ultra pH-sensitive tumor delivery platform improves tolerability and promotes antitumor response in a preclinical model
Presenter: Jason Miller, Ph.D., Associate Director, Research Pipeline Development, OncoNano Medicine
Date: Friday, November 3, 2023
Time: 9:00 a.m. ? 7:00 p.m. PT
Location: Exhibit Hall B ? San Diego Convention Center
Poster Number: 1147-B
About OncoNano Medicine
OncoNano Medicine is developing a new class of cancer products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat solid tumors with high specificity. Our polymeric micelles are designed to efficiently deliver oncology payloads to the tumor microenvironment for an enhanced therapeutic index. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, a platform of immuno-oncology therapeutics that activate and guide the body's immune system to target cancer, and agents for real-time image guided surgery.
ONM-501, OncoNano's first therapeutic program, is a next generation dual-activating STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the fourth quarter of 2023. OncoNano's second therapeutic development program is ONM-412, the highly potent pro-inflammatory cytokine, interleukin-12 (IL-12), encapsulated in the ON-BOARDtm polymeric micelle system. Additionally, the ON-BOARDtm platform has been used for pegsitacianine, a novel fluorescent nanoprobe that is being studied as a real-time surgical imaging agent for use in multiple cancer surgeries and is advancing towards a pivotal clinical trial to aid in tumor detection of peritoneal carcinomatosis. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas (CPRIT). Learn more at www.OncoNano.com.
News published on and distributed by:
